Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JNJ-86974680 + Pasritamig |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JNJ-86974680 | JNJ 86974680|JNJ86974680 | Adenosine Targeting 24 | JNJ-86974680 is an antagonist of the adenosine receptor A2AR (ADORA2A) expressed on T-lymphocytes, which may relieve adenosine-mediated immune suppression and enhance antitumor activity (Cancer Res (2025) 85 (8_Supplement_2): CT137; NCI Drug Dictionary). | |
| Pasritamig | JNJ78278343|JNJ 78278343|JNJ-78278343 | CD3 Antibody 120 | Pasritamig (JNJ-78278343) is an IgG1 bispecific antibody that targets KLK2 on tumor cells and CD3 on T-lymphocytes, which may lead to T-lymphocyte activation and killing of tumor cells expressing KLK2 (PMID: 40450573). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07319871 | Phase I | JNJ-86974680 + Pasritamig | A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer | Recruiting | USA | 0 |